Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
Authors
Keywords
Biomarkers, Canagliflozin, Chronic kidney disease, Sodium–glucose cotransporter 2 inhibitors, Type 2 diabetes
Journal
DIABETOLOGIA
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2019-04-18
DOI
10.1007/s00125-019-4859-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Astilbin inhibits high glucose-induced autophagy and apoptosis through the PI3K/Akt pathway in human proximal tubular epithelial cells
- (2018) Fang Chen et al. BIOMEDICINE & PHARMACOTHERAPY
- High glucose reduces megalin-mediated albumin endocytosis in renal proximal tubule cells through protein kinase BO-GlcNAcylation
- (2018) Diogo de Barros Peruchetti et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial
- (2018) Katherine R Tuttle et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice
- (2017) Atsuo Tahara et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Study of IL4-590C/T and IL6-174G/C Gene Polymorphisms in Type 2 Diabetic Patients With Chronic Kidney Disease in North Indian Population
- (2017) Km Neelofar et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Plasma Biomarkers and Kidney Function Decline in Early and Established Diabetic Kidney Disease
- (2017) Steven G. Coca et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update
- (2017) Hua Su et al. Frontiers in Immunology
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
- (2016) Hiddo J. L. Heerspink et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
- (2016) Vlado Perkovic et al. KIDNEY INTERNATIONAL
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors: β blockers for the kidney?
- (2016) Richard E Gilbert Lancet Diabetes & Endocrinology
- Drugs meeting the molecular basis of diabetic kidney disease: bridging from molecular mechanism to personalized medicine
- (2015) Hiddo J. Lambers Heerspink et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker
- (2015) Wenjun Ju et al. Science Translational Medicine
- Association of Serum Concentration of TNFR1 With All-Cause Mortality in Patients With Type 2 Diabetes and Chronic Kidney Disease: Follow-up of the SURDIAGENE Cohort
- (2014) Pierre-Jean Saulnier et al. DIABETES CARE
- Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus
- (2013) Damayanthi Devineni et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Kidney Disease and Increased Mortality Risk in Type 2 Diabetes
- (2013) M. Afkarian et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
- (2013) William T Cefalu et al. LANCET
- Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?
- (2013) Usha Panchapakesan et al. PLoS One
- Circulating TNF Receptors 1 and 2 Predict Stage 3 CKD in Type 1 Diabetes
- (2012) T. Gohda et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Circulating TNF Receptors 1 and 2 Predict ESRD in Type 2 Diabetes
- (2012) M. A. Niewczas et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
- (2012) Caroline S Fox et al. LANCET
- The proximal tubule in the pathophysiology of the diabetic kidney
- (2011) Volker Vallon AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Serum MMP-7 is increased in diabetic renal disease and diabetic diastolic dysfunction
- (2010) C.R. Ban et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
- (2008) J. F. List et al. DIABETES CARE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started